Summary of Study ST000440
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000339. The data can be accessed directly via it's Project DOI: 10.21228/M81S4N This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000440 |
Study Title | Metabotypes of Subjects with Adverse Reactions Following Vaccination |
Study Type | Metabolomic Profile of Human Serum |
Study Summary | Metabolomics may help identify a particular metabolic signature “metabotype” in patients who are predisposed to developing AEFI such as a systemic reaction, or myocarditis that currently is difficult or impossible to identify prior to the development of the AEFI. This proposed pilot study looks at the metabolic profiles of a specific population of subjects who received the smallpox vaccine with or without other concomitantly administered vaccines to help determine if a unique metabotype can be identified in subjects who reported systemic reactions following immunization. In addition, this proposed study will look at the metabolic profile of several subjects with subclinical or clinically diagnosed myopericarditis to determine if these subjects have a unique metabotype. The ability to identify a unique metabotype would allow a clinician to potentially mitigate serious AEFI and ultimately improve the quality of immunization healthcare. If identified, these profiles might represent novel biomarkers of risk that can supplement existing clinical decision making for risk stratification or vaccine exemptions. |
Institute | University of North Carolina |
Department | RCMRC |
Laboratory | Sumner Lab |
Last Name | Sumner |
First Name | Susan |
Address | Eastern Regional Comprehensive Metabolomics Resource Core, UNC Nutrition Research Institute, 500 Laureate Way, Kannapolis, NC, 28081 |
susan_sumner @unc.edu | |
Phone | 704-250-5066 |
Submit Date | 2016-08-02 |
Num Groups | 4 |
Total Subjects | 200 |
Num Males | 190 |
Num Females | 10 |
Raw Data Available | Yes |
Analysis Type Detail | NMR |
Release Date | 2016-09-23 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000339 |
Project DOI: | doi: 10.21228/M81S4N |
Project Title: | Metabotypes of Subjects with Adverse Reactions Following Vaccination: A Pilot Study |
Project Type: | Metabolomic Profile of Human Serum |
Project Summary: | An Adverse Event Following Immunization (AEFI) is an adverse reaction to a vaccination that goes above and beyond the usual side effects that are known to be associated with vaccinations. AEFIs can vary in clinical severity to very mild to incapacitating and occasionally require lost time from work or even hospitalization. In rare cases, there is an aberrant immune reaction from vaccination resulting in a potentially serious adverse event. One known serious adverse event related to the smallpox vaccine is myocarditis and/or pericarditis (myopericarditis). Metabolomics may help identify a particular metabolic signature “metabotype” in patients who are predisposed to developing AEFI such as a systemic reaction, or myocarditis that currently is difficult or impossible to identify prior to the development of the AEFI. This proposed pilot study looks at the metabolic profiles of a specific population of subjects who received the smallpox vaccine with or without other concomitantly administered vaccines to help determine if a unique metabotype can be identified in subjects who reported systemic reactions following immunization. In addition, this proposed study will look at the metabolic profile of several subjects with subclinical or clinically diagnosed myopericarditis to determine if these subjects have a unique metabotype. The ability to identify a unique metabotype would allow a clinician to potentially mitigate serious AEFI and ultimately improve the quality of immunization healthcare. If identified, these profiles might represent novel biomarkers of risk that can supplement existing clinical decision making for risk stratification or vaccine exemptions. |
Institute: | Defense Health Agency - Immunization Healthcare Branch and Womack Army Medical Center |
Department: | Immunization |
Last Name: | McClenathan |
First Name: | Bruce |
Address: | 1-2532 Armistead Street, Fort Bragg, NC 28310 |
Email: | bruce.m.mcclenathan.civ@mail.mil |
Phone: | (910) 432-4015 |
Subject:
Subject ID: | SU000461 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Human |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Gender | Group Number |
---|---|---|---|
SA022149 | S_59 | 1 | 1 |
SA022150 | S_40 | 1 | 1 |
SA022151 | S_27 | 1 | 1 |
SA022152 | S_60 | 1 | 1 |
SA022153 | S_28 | 1 | 1 |
SA022154 | S_39 | 1 | 1 |
SA022155 | S_7 | 1 | 1 |
SA022156 | S_8 | 1 | 1 |
SA022157 | S_62 | 1 | 1 |
SA022158 | S_9 | 1 | 2 |
SA022159 | S_26 | 1 | 2 |
SA022160 | S_24 | 1 | 2 |
SA022161 | S_23 | 1 | 2 |
SA022162 | S_25 | 1 | 2 |
SA022163 | S_29 | 1 | 2 |
SA022164 | S_32 | 1 | 2 |
SA022165 | S_31 | 1 | 2 |
SA022166 | S_30 | 1 | 2 |
SA022167 | S_3 | 1 | 2 |
SA022168 | S_22 | 1 | 2 |
SA022169 | S_20 | 1 | 2 |
SA022170 | S_188 | 1 | 2 |
SA022171 | S_189 | 1 | 2 |
SA022172 | S_187 | 1 | 2 |
SA022173 | S_18 | 1 | 2 |
SA022174 | S_17 | 1 | 2 |
SA022175 | S_190 | 1 | 2 |
SA022176 | S_191 | 1 | 2 |
SA022177 | S_2 | 1 | 2 |
SA022178 | S_33 | 1 | 2 |
SA022179 | S_194 | 1 | 2 |
SA022180 | S_193 | 1 | 2 |
SA022181 | S_192 | 1 | 2 |
SA022182 | S_21 | 1 | 2 |
SA022183 | S_35 | 1 | 2 |
SA022184 | S_50 | 1 | 2 |
SA022185 | S_51 | 1 | 2 |
SA022186 | S_5 | 1 | 2 |
SA022187 | S_49 | 1 | 2 |
SA022188 | S_48 | 1 | 2 |
SA022189 | S_52 | 1 | 2 |
SA022190 | S_53 | 1 | 2 |
SA022191 | S_57 | 1 | 2 |
SA022192 | S_58 | 1 | 2 |
SA022193 | S_56 | 1 | 2 |
SA022194 | S_55 | 1 | 2 |
SA022195 | S_54 | 1 | 2 |
SA022196 | S_47 | 1 | 2 |
SA022197 | S_46 | 1 | 2 |
SA022198 | S_38 | 1 | 2 |
SA022199 | S_16 | 1 | 2 |
SA022200 | S_37 | 1 | 2 |
SA022201 | S_36 | 1 | 2 |
SA022202 | S_6 | 1 | 2 |
SA022203 | S_4 | 1 | 2 |
SA022204 | S_41 | 1 | 2 |
SA022205 | S_45 | 1 | 2 |
SA022206 | S_44 | 1 | 2 |
SA022207 | S_43 | 1 | 2 |
SA022208 | S_42 | 1 | 2 |
SA022209 | S_34 | 1 | 2 |
SA022210 | S_19 | 1 | 2 |
SA022211 | S_14 | 1 | 2 |
SA022212 | S_11 | 1 | 2 |
SA022213 | S_15 | 1 | 2 |
SA022214 | S_12 | 1 | 2 |
SA022215 | S_13 | 1 | 2 |
SA022216 | S_10 | 1 | 2 |
SA022217 | S_106 | 1 | 3 |
SA022218 | S_107 | 1 | 3 |
SA022219 | S_109 | 1 | 3 |
SA022220 | S_110 | 1 | 3 |
SA022221 | S_108 | 1 | 3 |
SA022222 | S_105 | 1 | 3 |
SA022223 | S_67 | 1 | 3 |
SA022224 | S_63 | 1 | 3 |
SA022225 | S_103 | 1 | 3 |
SA022226 | S_111 | 1 | 3 |
SA022227 | S_104 | 1 | 3 |
SA022228 | S_65 | 1 | 3 |
SA022229 | S_114 | 1 | 3 |
SA022230 | S_121 | 1 | 3 |
SA022231 | S_120 | 1 | 3 |
SA022232 | S_122 | 1 | 3 |
SA022233 | S_123 | 1 | 3 |
SA022234 | S_124 | 1 | 3 |
SA022235 | S_119 | 1 | 3 |
SA022236 | S_118 | 1 | 3 |
SA022237 | S_68 | 1 | 3 |
SA022238 | S_113 | 1 | 3 |
SA022239 | S_115 | 1 | 3 |
SA022240 | S_116 | 1 | 3 |
SA022241 | S_117 | 1 | 3 |
SA022242 | S_112 | 1 | 3 |
SA022243 | S_69 | 1 | 3 |
SA022244 | S_90 | 1 | 3 |
SA022245 | S_91 | 1 | 3 |
SA022246 | S_100 | 1 | 3 |
SA022247 | S_89 | 1 | 3 |
SA022248 | S_87 | 1 | 3 |
Collection:
Collection ID: | CO000455 |
Collection Summary: | Serum was collected in accordance with standard operating procedures. |
Sample Type: | Blood |
Treatment:
Treatment ID: | TR000475 |
Treatment Summary: | Two-hundred sera samples – 100 baseline (pre-vaccine) and 100 post-smallpox vaccination |
Sample Preparation:
Sampleprep ID: | SP000468 |
Sampleprep Summary: | A total of 200 study samples were thawed on ice for sample preparation, 400 uL of the thawed serum sample were transferred to labeled tubes on ice where they were mixed with 1200uL of MeOH. Analytical quality control (QC) phenotypic pooled samples (3/Group) were generated by transferring pre-determined volumes of each sample from each respective phenotypic Group’s experimental samples into four different 2.0 mL LoBind tubes. The Phenotypic Pool tubes were vortexed, and 3 aliquots of 400 uL was transferred to Phenotypic Pool tubes for each Group. In addition, a study pool was generated by transferring 200 uL of serum from 25 randomly selected experimental samples into a 10.0 mL tube, vortexed and aliquoted into 10 Study Pool tubes. Methanol was added to all tubes (1200 uL), sample tubes were vortexed for 2 min on a multi-tube vortexer and centrifuged at 16,000 rcf for 5 min. A 1000 µl aliquot of the supernatant was transferred into new pre-labeled 2.0 mL LoBind tubes and lyophilized to complete dryness overnight. Samples were reconstituted with 700 uL of NMR Master Mix solution containing Chenomx ISTD: DSS-d6 and D2O-Phosphate Buffer at 7.4 pH. The tubes were vortexed for 4 min on a multi-tube vortexer and centrifuged at 16,000 rcf for 5 min. A 600 uL of each sample supernatant was transferred into a pre-labeled 5mm 4 NMR tubes for data acquisition on a 700 MHz spectrometer. |
Analysis:
Analysis ID: | AN000691 |
Analysis Type: | NMR |
Num Factors: | 8 |
NMR:
NMR ID: | NM000076 |
Analysis ID: | AN000691 |
Instrument Name: | Bruker |
Instrument Type: | FT-NMR |
NMR Experiment Type: | 1D 1H |
Field Frequency Lock: | Deuterium |
Standard Concentration: | 0.5mM |
Spectrometer Frequency: | 700 MHz |
NMR Probe: | 5mm ATMA Cryoprobe |
NMR Solvent: | D2O |
NMR Tube Size: | 5mm |
Shimming Method: | Topshim |
Water Suppression: | yes |
Receiver Gain: | 4.5 |
Offset Frequency: | 3299 |
Chemical Shift Ref Cpd: | DSS |
Temperature: | 298.1K |
Number Of Scans: | 128 |
Dummy Scans: | 4 |
Acquisition Time: | 3.893s |
Relaxation Delay: | 2s |
Spectral Width: | 12.0277ppm |
Num Data Points Acquired: | 65536 |
Real Data Points: | 65536 |
Line Broadening: | 0.5Hz |
Zero Filling: | yes |
Apodization: | Lorentzian |
Baseline Correction Method: | Polynomial |
Chemical Shift Ref Std: | DSS-d6 |
Binned Increment: | 0.04ppm |